High-Value Federal Grants ($5M+) — March 25, 2026

$928M across three contracts (Elevance, Emergent, RTI) with $616M already outlayed signals steady cash flows in Medicare IT and biopharma manufacturing.

$204M firm commitments to ElbitAmerica (DHS) and Pyramid Systems (GSA/HUD) with no outlay yet position for revenue inflection post-Mar 2026 starts, extendable to 2030.

$3.21B (74%) to nonprofits (Caltech, RTI, Mount Sinai) in space/health R&D limits direct investment alpha despite massive scales and $2.6B outlayed.

Long tenors (avg ~3-10 yrs to 2027-2030) with $1.1B unoutlayed expose to delays/funding cuts; $0 outlay on $204M new awards delays revenue.

Foreign-owned entities (Emergent Canada, ElbitAmerica) in pharma/border security face scrutiny amid DHS/HHS policy shifts.

Firm fixed-price ($527M) and T&M ($100M) structures risk overruns; high subawards (avg 10% of value) dilute primes' margins.

$200M+ unexercised options across contracts (e.g., Caltech $202M, Emergent $284M, Mount Sinai $44M) plus extensions to 2029-2030.

HHS/GSA IT/services focus ($760M) amid CMS/HUD digitization; small biz set-asides favor Pyramid-like players.

HHS awards 4/7 contracts ($1.19B, 27%) span IT, pharma, analysis to 2027, with $434M outlayed.

$2.95B NASA JPL renewal + $105M DHS surveillance lock multi-year FFRDC/security funding to 2028-30.

{"entity"=>"Emergent BioSolutions", "reason"=>"$422M HHS VIGIV with $284M options/ext to 2029 offers largest for-profit upside.", "trigger"=>"option exercise or outlay >$300M"}

{"entity"=>"ElbitAmerica / Elbit Systems", "reason"=>"$105M DHS surveillance starts Mar 2026 with foreign-ownership risks but 2030 potential.", "trigger"=>"initial outlays or policy headwinds"}

{"entity"=>"Pyramid Systems", "reason"=>"Small biz $100M GSA/HUD IT BPA with woman/minority designations for repeat wins.", "trigger"=>"extension to Sep 2026 or new calls"}